Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Efficacy (as Assessed by Post-Bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-Related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.

Trial Profile

A Double-Blind, Placebo-Controlled Efficacy (as Assessed by Post-Bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-Related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Palovarotene (Primary)
  • Indications Emphysema
  • Focus Therapeutic Use
  • Acronyms TESRA
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Jun 2011 New source identified and integrated (European Clinical Trials Database).
    • 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top